Otonomy Initiates Phase 3 Clinical Trial of OTIVIDEX™ in Ménière’s Disease
July 26, 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced initiation...
Otonomy to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update
March 01, 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 01, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...
Otonomy Announces Multiple Presentations for Hearing Loss and Tinnitus Programs at Upcoming Association for Research in Otolaryngology Meeting
February 06, 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced seven data...
Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311
November 16, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Obtains Rights to Gacyclidine Data From Ipsen to Support Development of OTO-311 as a Treatment for Tinnitus
November 06, 2014 01:00 ET
|
Otonomy, Inc.
SAN DIEGO and PARIS, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative...